Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 10/02/20141 min de lecture
Serious Drug-Induced Liver Injury: Who Gets It? Who Doesn't? Why?; Public Conference; Request for Comments
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) is announcing a public conference entitled "Serious Drug-Induced Liver Injury (DILI): Who Gets It? Who Doesn't? Why?" This conference will be cosponsored with the Critical Path Institute (C-Path) and the Pharmaceutical Research and Manufacturers of America. Its purpose is to discuss, debate, and share views among stakeholders in the pharmaceutical industry, academia, health care providers, patient groups, and regulatory bodies on how best to detect and assess the severity, extent, and likelihood of drug causation of liver injury and dysfunction in people using drugs for any medical purpose.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →